Figure S12 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Year: 2023
Type: other
Abstract: Supplementary Figure 12: HLA-DR and NKG2D abundance on peripheral lymphocytes associate with longer progression free survival.
Authors: H. Josh Jang, Galen Hostetter, Alexander W. Macfarlane, Zachary Madaj, Eric A. Ross, Toshinori Hinoue, Justin R. Kulchycki, Ryan S. Burgos, Mahvish Tafseer, R. Katherine Alpaugh, Candice L. Schwebel, Rutika Kokate, Daniel M. Geynisman, Matthew R. Zibelman, Pooja Ghatalia, Peter W. Nichols, Woonbok Chung, Jozef Madzo, Noah M. Hahn, David I. Quinn, Jean-Pierre J. Issa, Michael J. Topper, Stephen B. Baylin, Hui Shen, Kerry S. Campbell, Peter A. Jones, Elizabeth R. Plimack
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4379013293